Acquisition by Peter Zippelius of 4149 shares of Catalent subject to Rule 16b-3
CTLT Stock | USD 63.48 0.01 0.02% |
Slightly above 54% of Catalent's private investors are presently thinking to get in. The analysis of overall sentiment of trading Catalent stock suggests that some investors are interested at this time. Catalent's investing sentiment can be driven by a variety of factors including economic data, Catalent's earnings reports, geopolitical events, and overall market trends.
Catalent |
Filed transaction by Catalent Inc director. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Cash Flow Correlation
Catalent's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Catalent's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Catalent Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Catalent can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Catalent Fundamental Analysis
We analyze Catalent's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Catalent using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Catalent based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Per Share
Cash Per Share Comparative Analysis
Catalent is currently under evaluation in cash per share category among its peers. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Catalent Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Catalent stock to make a market-neutral strategy. Peer analysis of Catalent could also be used in its relative valuation, which is a method of valuing Catalent by comparing valuation metrics with similar companies.
Peers
Catalent Related Equities
ORIC | Oric Pharmaceuticals | 6.76 | ||||
GLUE | Monte Rosa | 6.45 | ||||
LYRA | Lyra Therapeutics | 5.88 | ||||
INBX | Inhibrx | 5.19 | ||||
SNSE | Sensei Biotherapeutics | 4.65 | ||||
DSGN | Design Therapeutics | 4.34 | ||||
ERAS | Erasca | 3.67 | ||||
NXTC | NextCure | 2.11 | ||||
NUVB | Nuvation Bio | 0.37 | ||||
EPIX | ESSA Pharma | 0.62 |
Additional Tools for Catalent Stock Analysis
When running Catalent's price analysis, check to measure Catalent's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalent is operating at the current time. Most of Catalent's value examination focuses on studying past and present price action to predict the probability of Catalent's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalent's price. Additionally, you may evaluate how the addition of Catalent to your portfolios can decrease your overall portfolio volatility.